This report contains market size and forecasts of Targeted Drug ALK Inhibitors for NSCLC in Global, including the following market information:
Global Targeted Drug ALK Inhibitors for NSCLC Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Targeted Drug ALK Inhibitors for NSCLC market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Crizotinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Targeted Drug ALK Inhibitors for NSCLC include Pfizer, Novartis, Chugai Pharmaceutical (Hoffmann-La Roche group), ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Beacon Pharma Limited, Drug International Limted and Incepta Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Targeted Drug ALK Inhibitors for NSCLC companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Targeted Drug ALK Inhibitors for NSCLC Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Targeted Drug ALK Inhibitors for NSCLC Market Segment Percentages, by Type, 2021 (%)
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
Global Targeted Drug ALK Inhibitors for NSCLC Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Targeted Drug ALK Inhibitors for NSCLC Market Segment Percentages, by Application, 2021 (%)
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Global Targeted Drug ALK Inhibitors for NSCLC Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Targeted Drug ALK Inhibitors for NSCLC Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Targeted Drug ALK Inhibitors for NSCLC revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Targeted Drug ALK Inhibitors for NSCLC revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Chugai Pharmaceutical (Hoffmann-La Roche group)
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals